SAFETY SUBGROUP ANALYSES FROM THE CECOG PHASE III TURANDOT TRIAL: FIRST-LINE BEVACIZUMAB (BEV) IN COMBINATION WITH CAPECITABINE (X) OR PACLITAXEL (P) FOR HER2-NEGATIVE LOCALLY RECURRENT OR METASTATIC BREAST CANCER (LR/MBC)

被引：0
|
作者：
Lang, I. [1 ]
Inbar, M. [2 ]
Greil, R. [3 ]
Kahan, Z. [4 ]
Beslija, S. [5 ]
Steger, G. G. [6 ]
Stemmer, S. M. [7 ]
Zvribule, Z. [8 ]
Kaufman, B. [9 ]
Zielinski, C. [10 ,11 ]
机构：
[1] Natl Inst Oncol, Dept Med Oncol & Clin Pharmacol B, Budapest, Hungary
[2] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, IL-69978 Tel Aviv, Israel
[3] Med Univ Salzburg, Dept Med, Salzburg, Austria
[4] Univ Med Sch Szeged, Szeged, Hungary
[5] Inst Oncol, Sarajevo, Bosnia & Herceg
[6] Med Univ Vienna, Med & Canc Ctr, Vienna, Austria
[7] Davidoff Ctr, Petah Tiqwa, Israel
[8] Riga Eastern Hosp, Latvian Ctr Oncol, Riga, Latvia
[9] Chaim Sheba Med Ctr, Div Oncol, Ramat Gan, Israel
[10] Univ Hosp, Dept Med 1, Vienna, Austria
[11] Ctr Canc, Vienna, Austria
来源：
ANNALS OF ONCOLOGY | 2010年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：98 / 98
页数：1
相关论文
共 50 条
  • [21] Efficacy and safety of first-line bevacizumab (Bev) combined with paclitaxel (Pac): An observational study in 786 patients (pts) with HER2-negative metastatic breast cancer (mBC).
    Klare, P.
    Foerster, F. G.
    Geberth, M.
    Schneeweiss, A.
    Tesch, H.
    Kuemmel, S.
    Schumacher, C.
    Hollburg, W.
    Soeling, U.
    Schmidt, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [22] First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients
    Miles, D. W.
    Dieras, V.
    Cortes, J.
    Duenne, A. -A.
    Yi, J.
    O'Shaughnessy, J.
    ANNALS OF ONCOLOGY, 2013, 24 (11) : 2773 - 2780
  • [23] A randomized, placebo-controlled phase II study of AMG 386 plus bevacizumab (Bev) and paclitaxel (P) or AMG 386 plus P as first-line therapy in patients (pts) with HER2-negative, locally recurrent or metastatic breast cancer (LR/MBC)
    Dieras, V.
    Jassem, J.
    Dirix, L. Y.
    Guastalla, J. P.
    Bono, P.
    Hurvitz, S. A.
    Goncalves, A.
    Romieu, G.
    Limentani, S. A.
    Jerusalem, G. H. M.
    Lakshmaiah, K.
    Roche, H. H.
    Sanchez-Rovira, P.
    Pienkowski, T.
    Segui-Palmer, M. A.
    Li, A.
    Sun, Y.
    Pickett-Gies, C. A.
    Wildiers, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [24] Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer
    Vrdoljak, E.
    Marschner, N.
    Zielinski, C.
    Gligorov, J.
    Cortes, J.
    Puglisi, F.
    Aapro, M.
    Fallowfield, L.
    Fontana, A.
    Inbar, M.
    Kahan, Z.
    Welt, A.
    Levy, C.
    Brain, E.
    Pivot, X.
    Putzu, C.
    Gonzalez Martin, A.
    de Ducla, S.
    Easton, V.
    von Minckwitz, G.
    ANNALS OF ONCOLOGY, 2016, 27 (11) : 2046 - 2052
  • [25] Comparison of Subgroup Analyses of PFS from Three Phase III Studies of Bevacizumab in Combination with Chemotherapy in Patients with HER2-Negative Metastatic Breast Cancer (MBC).
    O'Shaughnessy, J.
    Dieras, V
    Glaspy, J.
    Brufsky, A.
    Miller, K. D.
    Miles, D. W.
    Koralewski, P.
    Phan, S-C
    Bhattacharya, S.
    CANCER RESEARCH, 2009, 69 (24) : 512S - 512S
  • [26] Exploratory analyses of candidate predictive and prognostic tissue biomarkers (BMs) in the open-label randomised phase III TANIA trial of bevacizumab (BEV) in HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)
    Zielinski, C.
    Gligorov, J.
    Marschner, N.
    Puglisi, F.
    Vrdoljak, E.
    Castan, J. Cortes
    de Ducla, S.
    Deurloo, R.
    Easton, V.
    von Minckwitz, G.
    ANNALS OF ONCOLOGY, 2016, 27
  • [27] Phase II study of bevacizumab (Bev) combined with weekly paclitaxel (wPac) as first-line therapy for Japanese patients (pts) with HER2-negative metastatic breast cancer (MBC).
    Masuda, N.
    Aogi, K.
    Ohno, S.
    Iwata, H.
    Kashiwaba, M.
    Fujiwara, Y.
    Ito, Y.
    Ueno, T.
    Saijo, N.
    Takashima, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [28] PACLITAXEL (P) AND BEVACIZUMAB (BEV), AS FIRST-LINE CHEMOTHERAPY, IN PATIENTS WITH HER2-NEGATIVE METASTATIC BREAST CANCER (MBC). THE HELLENIC COOPERATIVE ONCOLOGY GROUP EXPERIENCE WITH BIOMARKER EVALUATION
    Kourea, H. P.
    Koutras, A. K.
    Kotoula, V.
    Bobos, M.
    Fountzila, A. Kalogera
    Papazisis, K. T.
    Christodoulou, C.
    Res, E.
    Bournakis, E.
    Fountzilas, G.
    ANNALS OF ONCOLOGY, 2010, 21 : 104 - 104
  • [29] Overall survival (OS) in the IMELDA randomized phase III trial of maintenance bevacizumab (BEV) with or without capecitabine (CAP) for HER2-negative metastatic breast cancer (mBC)
    Gligorov, Joseph
    Bines, Jose
    Alba, Emilio
    Mustacchi, Giorgio
    Cinieri, Saverio
    Gupta, Vineet
    Pierga, Jean-Yves
    Bozcuk, Hakan
    Gaafar, Rabab
    Gupta, Sudeep
    Vivanco, Guillermo Lopez
    Wang, Xiaojia
    Costa, Romulo
    Altundag, Kadri
    Chmielowska, Ewa
    de Ducla, Sabine
    Freudensprung, Ulrich
    Cortes, Paulo
    Doval, Dinesh
    CANCER RESEARCH, 2015, 75
  • [30] Real-world effectiveness and safety of first-line bevacizumab (BEV) plus paclitaxel (PAC) in > 2000 patients (pts) with HER2-negative metastatic breast cancer (mBC)
    Mueller, V.
    Dank, M.
    de Ducla, S.
    Mitchell, L.
    Schneeweiss, A.
    ANNALS OF ONCOLOGY, 2016, 27
12345